Pharma-Bio Serv Announces Results for the Quarter Ended July 31, 2025

Rhea-AI Summary

Pharma-Bio Serv (OTCQB:PBSV), a consulting firm serving pharmaceutical and related industries, reported financial results for Q3 2025. The company posted revenues of $2.0 million for the quarter and $6.9 million for the nine months ended July 31, 2025, compared to $2.4 million and $7.2 million in the respective periods of 2024.

Despite lower revenues, the company reduced its net loss to $0.2 million for Q3 and $0.1 million for the nine-month period, representing improvements of $0.1 million and $0.7 million year-over-year, respectively. Management highlighted strategic initiatives including cost structure optimization and focus on core business segments.

Positive

• Net loss improvement of $0.1M for Q3 and $0.7M for nine months YoY
• Successful implementation of cost structure optimization
• Strategic exit from less profitable business segments
• Multiple significant projects ready for immediate commencement

Negative

• Revenue decline of 16.7% to $2.0M in Q3 2025 from $2.4M in Q3 2024
• Nine-month revenue decreased 4.2% to $6.9M from $7.2M YoY
• Continued net loss position of $0.2M in Q3 and $0.1M for nine months

News Market Reaction

%

1 alert

% News Effect

On the day this news was published, PBSV declined NaN%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

DORADO, PUERTO RICO / ACCESS Newswire / September 15, 2025 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that revenues for the three and nine months ended July 31, 2025 were approximately $2.0 million and $6.9, million, respectively. Revenues for the three and nine months ended July 31, 2024 were approximately $2.4 million and $7.2 million, respectively. Net loss for the three and nine months ended July 31, 2025 was approximately $0.2 million and $0.1 million, respectively, an earnings increase of approximately $0.1 million and $0.7 million when compared to the same periods last year, respectively.

"Over the past quarters, we have taken decisive steps to streamline our cost structure, prioritize core business segments, and exit less profitable areas. We believe these efforts have positioned the Company to capitalize on new opportunities with greater agility and focus. We are encouraged by the momentum building across our operations and are preparing for the immediate commencement of several significant projects. The Company remains committed to delivering long-term value to shareholders through disciplined execution," stated Mr. Sanchez Chief Executive Officer of the Company.

About Pharma-Bio Serv, Inc.
Pharma-Bio Serv services the Puerto Rico, United States, Europe and Latin America markets. Pharma-Bio Serv's core business is FDA and international agencies regulatory compliance consulting related services. The Company's global team includes leading engineering and life science professionals, quality assurance managers and directors.

Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the U.S. federal securities laws, which statements may include information regarding the plans, intentions, expectations, future financial performance, or future operating performance of Pharma-Bio Serv. Forward-looking statements are based on the expectations, estimates, or projections of management as of the date of this earnings announcement. Although Pharma-Bio Serv's management believes these expectations, estimates, or projections to be reasonable as of the date of this earnings announcement, forward-looking statements are inherently subject to significant business risks, economic uncertainties, and competitive uncertainties, and other factors, which could cause its actual results or performance to differ materially from what may be expressed or implied in the forward-looking statements. Important factors that could cause Pharma-Bio Serv's actual results or performance to differ materially from the forward-looking statements include those set forth in the "Risk Factors" section of Pharma-Bio Serv's Annual Report on Form 10-K for the year ended October 31, 2024, and in its other filings with the Securities and Exchange Commission, which filings are available at www.sec.gov. Pharma-Bio Serv disclaims any intention or obligation to update or revise any forward-looking statements to reflect subsequent events and circumstances, except to the extent required by applicable law.

Company Contact:
Pedro J. Lasanta
Chief Financial Officer
787 278 2709

SOURCE: Pharma-Bio Serv Inc.

View the original press release on ACCESS Newswire

FAQ

What were Pharma-Bio Serv's (PBSV) Q3 2025 revenue and earnings?

Pharma-Bio Serv reported Q3 2025 revenue of $2.0 million and a net loss of $0.2 million, showing revenue decline but improved bottom line compared to the same period last year.

How did PBSV's revenue change in the first nine months of 2025 compared to 2024?

PBSV's nine-month revenue decreased to $6.9 million in 2025 from $7.2 million in 2024, representing a 4.2% decline.

What strategic changes has Pharma-Bio Serv implemented in 2025?

The company has streamlined its cost structure, prioritized core business segments, and exited less profitable areas to improve operational efficiency and profitability.

How much did PBSV improve its net loss position in Q3 2025?

PBSV improved its net loss position by $0.1 million in Q3 and $0.7 million for the nine-month period compared to the same periods in 2024.